Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

被引：0
|
作者：
Pignata, S.
Scambia, G.
Savarese, A.
Sorio, R.
Breda, E.
Ferrandina, G.
Gebbia, V.
Musso, P.
Gallo, C.
Perrone, F.
机构：
[1] Ist Nazl Tumori, Naples, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Ist Regina Elena, I-00161 Rome, Italy
[4] CRO, Aviano, Italy
[5] Osped Fatebenefratelli, Rome, Italy
[6] Univ Palermo, Casa Cura La Maddalena, Palermo, Italy
[7] Osped Oncol, M Ascoli ARNAS, Palermo, Italy
[8] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
    Pignata, Sandro
    Scambia, Giovanni
    Schettino, Clorinda
    Arenare, Laura
    Pisano, Carmela
    Lombardi, Davide
    De Giorgi, Ugo
    Andreetta, Claudia
    Cinieri, Saverio
    De Angelis, Carmine
    Priolo, Domenico
    Casanova, Claudia
    Rosati, Marta
    Greco, Filippo
    Zafarana, Elena
    Schiavetto, Ilaria
    Mammoliti, Serafina
    Cecere, Sabrina Chiara
    Salutari, Vanda
    Scalone, Simona
    Farolfi, Alberto
    Di Napoli, Marilena
    Lorusso, Domenica
    Gargiulo, Piera
    Califano, Daniela
    Russo, Daniela
    Spina, Anna
    De Cecio, Rossella
    Chiodini, Paolo
    Perrone, Francesco
    LANCET ONCOLOGY, 2023, 24 (03): : 286 - 296
  • [42] A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with extensive disease small cell lung cancer
    Schmittel, A.
    Fischer von Weikersthal, L.
    Sebastian, M.
    Schulze, K.
    Link, H.
    Thiel, E.
    Keilholz, U.
    EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 328
  • [43] Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2-A randomized phase II trial
    Lorusso, D.
    Ferrandina, G.
    Colombo, N.
    Pignata, S.
    Pietragalla, A.
    Sonetto, C.
    Pisano, C.
    Lapresa, M. T.
    Savarese, A.
    Tagliaferri, P.
    Lombardi, D.
    Cinieri, S.
    Breda, E.
    Sabatucci, I.
    Sabbatini, R.
    Conte, C.
    Cecere, S. C.
    Maltese, G.
    Scambia, G.
    GYNECOLOGIC ONCOLOGY, 2019, 155 (03) : 406 - 412
  • [44] Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial
    Schmittel, A. H.
    Sebastian, M.
    von Weikersthal, L. Fischer
    Gauler, T.
    Hortig, P.
    Fischer, J. R.
    Link, H.
    Binder, D.
    Eberhardt, W.
    Keilholz, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR).
    Sehouli, Jalid
    Meier, Werner
    Wimberger, Pauline
    Chekerov, Radoslav
    Belau, Antje
    Mahner, Sven
    Kurzeder, Christian
    Hilpert, Felix
    Klare, Peter
    Doerfel, Steffen
    Strauss, Hans-Georg
    Canzler, Ulrich
    Marth, Christian
    Reinthaller, Alexander
    Petru, Edgar
    Richter, Rolf
    Rubio, Maria Jesus
    Bover, Isabel
    Gonzalez-Martin, Antonio
    Harter, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC)
    Sugio, K.
    Nagashima, A.
    Nakanishi, R.
    Uchiyama, A.
    Inoue, M.
    Osaki, T.
    Yoshimatsu, T.
    Takenoyama, M.
    Hanagiri, T.
    Yasumoto, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
    Parmar, MKB
    Adams, M
    Balestrino, M
    Bertelsen, K
    Bonazzi, C
    Calvert, H
    Colombo, N
    Delaloye, JF
    Durando, A
    Guthrie, D
    Hagen, B
    Harper, P
    Mangioni, C
    Perren, T
    Poole, C
    Qian, W
    Rustin, G
    Sandercock, J
    Tumolo, S
    Torri, V
    Vecchione, F
    LANCET, 2002, 360 (9332): : 505 - 515
  • [48] Paclitaxel (175 mg/m(2)) plus carboplatin versus paclitaxel (225 mg/m(2)) plus carboplatin in non-small cell lung cancer: A randomized study
    Kosmidis, P
    Mylonakis, N
    Fountzilas, G
    Samantas, E
    Athanassiadis, A
    Pavlidis, N
    Skarlos, D
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : 30 - 33
  • [49] Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer - A multicenter phase II trial
    Potamianou, A
    Androulakis, N
    Papakotoulas, P
    Toufexi, H
    Latoufis, C
    Kouroussis, C
    Christofilakis, C
    Xenidis, N
    Georgoulias, V
    Polyzos, A
    ONCOLOGY, 2005, 69 (04) : 348 - 353
  • [50] A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7)-European Network of Gynaecological Oncological Trial Groups (ENGOT -ov-10) and Gynecologic Cancer Intergroup (GCIG) trial.
    Pignata, Sandro
    Scambia, Giovanni
    Lauria, Rossella
    Raspagliesi, Francesco
    Panici, Pierluigi Benedetti
    Cormio, Gennaro
    Katsaros, Dionyssios
    Sorio, Roberto
    Cavazzini, Giovanna
    Ferrandina, Gabriella
    Breda, Enrico
    Murgia, Viviana
    Sacco, Cosimo
    Sierra, Nuria Maria Asensio
    Pisano, Carmela
    Salutari, Vanda
    Weber, Beatrice E.
    Pujade-Lauraine, Eric
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
12345